To include your compound in the COVID-19 Resource Center, submit it here.

X4 reports Phase II data for WHIM syndrome candidate

X4 Pharmceuticals Inc. (Cambridge, Mass.) reported preliminary data from five evaluable patients with warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE